SequelSEC

Drugs Made In America Acquisition II Corp. DMII

Blank Checks · CIK 0002040475 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$488.38K
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

How this compares in its industry

Percentile among the Blank Checks filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.09x27th

Drugs Made In America Acquisition II Corp. (DMII) reported net income of $4.19M for the fiscal year ended 2025-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Drugs Made In America Acquisition II Corp.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Blank Checks.

Income

Drugs Made In America Acquisition II Corp. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$488.38K
Net income$4.19M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$488.38K
Selling & marketingUnavailable

Balance

Drugs Made In America Acquisition II Corp. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Cash & equivalents$223
Total assets$504.96M
Current assets$26.04K
Total liabilities$17.80M
Current liabilities$300.86K
Total equity incl. NCI-$17.77M
Temporary (mezzanine) equity$504.93M
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$99.36K

Cash flow

Drugs Made In America Acquisition II Corp. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Operating cash flow-$1.02M
Capital expendituresUnavailable
Investing cash flow-$500.00M
Financing cash flow$501.00M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Drugs Made In America Acquisition II Corp. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.09x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DMII in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-11-18View SEC filing

Companies in the same industry

AACI AACO ADAC AEAQ AESP AEXA AFJK AIIA ALCYF ALDA ALDF ALFUU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.